Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03051893
Recruitment Status : Completed
First Posted : February 14, 2017
Last Update Posted : February 14, 2017
Sponsor:
Collaborator:
Simbec Research
Information provided by (Responsible Party):
Diurnal Limited

Brief Summary:
This was an open label, randomised, single dose study, comprising Part A (undertaken in two separate three-period crossover cohorts denoted as A1 and A2) and Part B (undertaken in one four-period crossover cohort), to evaluate the PK of Chronocort® in healthy male volunteers. The washout interval in both Part A and Part B was 1-week in between each treatment period.

Condition or disease Intervention/treatment Phase
Adrenal Insufficiency Congenital Adrenal Hyperplasia Drug: Chronocort Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Two-part Open Label, Randomised, Single Dose, Crossover Study in Healthy Volunteers to: (Part A) Compare the Pharmacokinetics of up to 6 Chronocort® Formulations, and (Part B) Determine the Dose Proportionality of a Selected Chronocort® Formulation at Three Dose Levels With an Additional Comparison With the Selected Formulation Dosed on Two Occasions Over a 24 Hour Period
Study Start Date : February 2011
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012


Arm Intervention/treatment
Experimental: Part A1
Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
Drug: Chronocort
Modified formulation of hydrocortisone

Experimental: Part A2
Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
Drug: Chronocort
Modified formulation of hydrocortisone

Experimental: Part B
The best formulation of Chronocort was then selected from Parts A1 & A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.
Drug: Chronocort
Modified formulation of hydrocortisone




Primary Outcome Measures :
  1. To compare the Tmax of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. Parts A1 & A2 only [ Time Frame: 18 hours ]
    Time at maximum concentration in serum

  2. To compare the Cmax of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. Parts A1 & A2 only [ Time Frame: 18 hours ]
    Maximum serum concentration

  3. To compare the AUC0-t of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. [ Time Frame: 18 hours ]
    Area under the plasma concentration-time curve

  4. To compare the AUC0-∞ of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. [ Time Frame: 18 hours ]
    Area under the plasma concentration-time curve from zero (0) hours to infinity (∞)

  5. To compare the CL of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. [ Time Frame: 18 hours ]
    Drug clearance (CL) is defined as the volume of plasma in the vascular compartment cleared of drug per unit time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteers between 18 and 60 years of age, inclusive (at screening).
  • Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))2.
  • Subjects with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 14 days prior to the first dose.
  • Subjects with negative urinary drugs of abuse screen determined within 14 days prior to the first dose.
  • Subjects with negative HIV and Hepatitis B and C results.
  • Subjects with no clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 14 days prior to the first dose.
  • Subjects with no clinically-significant deviation outside the normal ranges for blood pressure and pulse measurements.
  • Subjects and sexual partners used effective contraception methods during the trial and for 3 months after the last dose, for example:

    • Oral contraceptive and condom
    • Intra-uterine device (IUD) and condom
    • Diaphragm with spermicide and condom
  • Subjects were available to complete the study.
  • Subjects satisfied a medical examiner about their fitness to participate in the study.
  • Subjects provided written informed consent to participate in the study.
  • Subject continued to meet all screening inclusion criteria prior to dosing.
  • Subjects with no clinically significant abnormal serum biochemistry, haematology and urine examination values including negative urinary drugs of abuse screen (including alcohol) prior to dosing.

Exclusion Criteria:

  • A clinically significant history of gastrointestinal disorder likely to influence drug absorption.
  • Receipt of regular medication within 14 days prior to the first dose (including high dose vitamins, dietary supplements or herbal remedies).
  • Receipt of any vaccination within 14 days prior to the first dose.
  • Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
  • Presence of clinically significant infections (systemic fungal and viral infections, acute bacterial infections)
  • Current or previous history of tuberculosis
  • A clinically significant history of previous allergy / sensitivity to Hydrocortisone and/or Dexamethasone.
  • A clinically significant history or family history of psychiatric disorders/illnesses.
  • A clinically significant history of drug or alcohol abuse.
  • Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
  • Participation in a New Chemical Entity clinical study within the previous 16 weeks or a marketed drug clinical study within the previous 12 weeks. (N.B. The washout period between trials was defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study)
  • Subjects who have consumed more than 2 units of alcohol per day within seven (7) days prior to the first dose or have consumed any alcohol within the 48 hour period prior to the first dose.
  • Donation of 450ml or more of blood within the previous 12 weeks.
  • Subjects who smoked (or ex-smokers who had smoked within 6 months prior to first dose).
  • Subjects who worked shifts (i.e. regularly alternated between days, afternoons and nights).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03051893


Sponsors and Collaborators
Diurnal Limited
Simbec Research
Investigators
Layout table for investigator information
Principal Investigator: Girish Sharma Simbec Research
Layout table for additonal information
Responsible Party: Diurnal Limited
ClinicalTrials.gov Identifier: NCT03051893    
Other Study ID Numbers: DIUR-002
First Posted: February 14, 2017    Key Record Dates
Last Update Posted: February 14, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenal Hyperplasia, Congenital
Adrenogenital Syndrome
Adrenal Insufficiency
Hyperplasia
Pathologic Processes
Adrenal Gland Diseases
Endocrine System Diseases
Disorders of Sex Development
Urogenital Abnormalities
Congenital Abnormalities
Genetic Diseases, Inborn
Steroid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Metabolic Diseases
Gonadal Disorders